Eli Lilly Collaborates with Superluminal Medicines to Develop Small Molecule for Cardiometabolic Diseases and Obesity

Shots:

• Superluminal Medicines & Eli Lilly have partnered to develop small molecule therapeutics for undisclosed GPCR targets in cardiometabolic diseases & obesity, leveraging Superluminal’s drug discovery platform
• As per the deal, Superluminal will use its platform to discover & optimize small molecules, while Lilly will obtain exclusive rights to develop & commercialize the candidates in exchange for ~$1.3B, which incl. upfront, near-term payments, equity investment, development & commercial milestones as well as tiered royalties
• Superluminal’s platform combines structural biology, ML, & proprietary PK/toxicology prediction tools in a predict-design-test framework to model protein shapes & design selective small molecules for precise therapeutic effects

Ref: Superluminal | Image: Superluminal and Eli Lilly| Press Release

Related News:- Basilea Pharmaceutica Enters Into a Licensing Deal with Venatorx Pharmaceuticals

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com